ADPT Chief Scientific Officer Harlan Robins Sells $111K of Stock

Harlan Robins, the Chief Scientific Officer of Adaptive Biotechnologies Corporation, sold 6,160 shares of the company on June 16, 2026. The shares were sold at an average price of $18.01, amounting to a total transaction value of approximately $110,941.6. This sale was conducted under a pre-planned trading program.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

In addition to Harlan Robins' recent sale, there have been other insider transactions at Adaptive Biotechnologies. Robins sold 100,000 shares on June 15, 2026, at $17.37 per share. Susan Bobulsky, Chief Commercial Officer, MRD, sold 5,000 shares on June 11, 2026, at $19.00 each. Francis Lo, Chief People Officer, had multiple transactions on June 4, 2026, including a sale of 39,741 shares at $17.49 under a planned program.

Other Institutional Activity in Adaptive Biotechnologies

Viking Global Investors LP holds a substantial position in Adaptive Biotechnologies, with 29,993,708 shares valued at about $416.31 million, with no recent change in their holdings. BlackRock, Inc. trimmed its position slightly by 30,534 shares, ending with 13,303,025 shares worth approximately $184.65 million. Vanguard Capital Management LLC added 6,094,144 shares, bringing its total to the same number, valued at $84.59 million. Westfield Capital Management Co LP increased its stake by 1,376,237 shares, holding 5,436,718 shares valued at about $75.46 million.

Adaptive Biotechnologies Corporation Stock Down 32.7%

Shares of NasdaqGS:ADPT traded near $17.07. The company has a market capitalization of approximately $2.76 billion. It is not currently profitable, as indicated by its negative forward P/E ratio of -68.10. The stock has experienced a 52-week low of $9.96 and a high of $20.76. Its 50-day moving average stands at $14.69, with a 200-day moving average of $15.42. The company has a beta of 2.151, reflecting higher volatility, and maintains a current ratio of 3.35, with a quick ratio of 3.08. Its debt-to-equity ratio is 92.84.

Recent Earnings

Adaptive Biotechnologies reported revenue of $295.41 million, reflecting a growth of 35.1%. However, the company posted a net margin of -16.82% and a return on equity of -23.96%. The next earnings report is scheduled for August 4, 2026.

Analysts Set New Price Targets

On May 12, 2026, Morgan Stanley maintained a 'hold' rating with an $18.00 price target. JP Morgan and TD Cowen both maintained 'buy' ratings on May 6, 2026, with targets of $19.00 and $21.00, respectively. The consensus among analysts is a 'strong buy' with a mean target price of $20.14, based on seven opinions.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, headquartered in Seattle, Washington, operates in the healthcare sector, focusing on diagnostics and research. The company has developed an immune medicine platform that aids in diagnosing and treating various diseases. Its clonoSEQ test is notable for detecting minimal residual disease in cancer patients. Led by CEO Chad M. Robins, the company employs 624 people.

Bottom Line

Harlan Robins' planned sale of shares highlights ongoing insider activity at Adaptive Biotechnologies. The company's stock has shown volatility, with a recent trading price near $17.07. Institutional investors like Viking Global and BlackRock have significant stakes, reflecting interest in the company's potential. As always, remember that insider transactions and 13F filings are backward-looking and may not represent current positions.